Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis

Autor(es)

Mello-Bosnic, Claudia ^[1] ; Gimenes, Alexandre Dantas ^[2] ; Oliani, Sonia Maria ^[1] ; Gil, Cristiane Damas ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] UNESP Univ Estadual Paulista, Programa Posgrad Biociencias, Inst Biociencias Letras & Ciencias Exatas, Sao Jose Do Rio Preto, SP - Brazil

^[2] UNIFESP Univ Fed Sao Paulo, Dept Morfol & Genet, Rua Botucatu 740, Ed Lemos Torres 3 Andar, BR-04023900 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: European Journal of Pharmacology; v. 833, p. 124-130, AUG 15 2018.
• Citações Web of Science: 1

Resumo

Galectin-1 (Gal-1) is a beta-galactoside-binding protein with diverse biological activities in the pathogenesis of inflammation, however the mechanisms by which Gal-1 modulates cellular responses in allergic inflammatory processes have not been fully determined. In this study, we evaluated the therapeutic potential of Gal-1 eye drops in an experimental model of conjunctivitis. Wistar rats received a topical application of compound (C)48/80 (100 mg/ml) into right eyes and a drop of vehicle into the contralateral eye. Another group of rats received Gal-1 (0.3 or 3 mu g/eye) or sodium cromoglycate (SCG; 40 mg/ml) in both eyes and, after 15 min, right eye was challenged with C48/80. Conjunctivitis-induced by C48/80 was characterized by severe eyelid oedema and tearing, but clinical signs were ameliorated by eye drop doses of both Gal-1 (0.3/3 mu g) and SCG. As expected, an increased proportion of degranulated mast cells (62%, P < 0.01) and lower histamine levels were observed after 6 h of C48/80 challenge, compared to control (32%). This effect was abrogated by Gal-1 and SCG, which reduced mast cell degranulation (31-36%), eosinophil migration and eosinophil peroxidase levels in the eyes. Gal-1 (3 mu g) and SCG treatments also decreased IL-4 levels, as well as activation of mitogen activated protein kinases compared to untreated C48/80 eyes. Our findings suggest that Gal-1 eye drops represent a new therapeutic strategy for ocular allergic inflammation. (AU)

• Processo FAPESP: 16/02012-4 - Investigação das atividades imunomoduladoras da proteína anexina A1 na regulação inflamatória de doenças do sistema gastrointestinal: estudo em modelos experimentais in vivo e in vitro
• Beneficiário: Sonia Maria Oliani
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 15/09858-3 - Mecanismos de ação das proteínas galectinas-1 e -3 na inflamação alérgica: Estudo em modelos experimentais in vivo e in vitro e em pacientes alérgicos
• Beneficiário: Cristiane Damas Gil
• Modalidade de apoio: Auxílio à Pesquisa - Regular